Mechanical heart valve prostheses: identification and evaluation

Identification of mechanical prosthetic heart valves based on distinctive cinefluoroscopic and echocardiographic markers

The past 65 years have witnessed remarkable progress in the development of safe, hemodynamically favorable mechanical heart valves. Today, there are a large number and variety of prostheses in use and many prostheses have been used for a while and then discontinued. When patients lack reliable information about their heart valve prostheses, identification of valve model becomes difficult even for specialized physicians in this area. A combination of cinefluoroscopy and echocardiography makes it possible to provide accurate and detailed information regarding identification of prosthetic valve models. Fluoroscopic examination is a useful technique to evaluate patients following mechanical heart valve replacement. However, transthoracic echocardiography and transesophageal echocardiography have almost replaced cinefluoroscopy in the evaluation of prosthetic heart valves. Especially, real-time three-dimensional transesophageal echocardiography provides distinctive images of prosthetic heart valves, particularly for those in the mitral position. A large body of literature has been published to familiarize physicians with the radiological appearance of numerous mechanical prostheses. However, there is a lack of data regarding the identification of prosthetic valve models based on echocardiographic appearance. In this review, we aimed to describe distinctive echocardiographic and cinefluoroscopic markers for identifying the type and brand of several commonly used mechanical prosthetic heart valves.

A turbulence in vitro assessment of On-X and St Jude Medical prostheses

OBJECTIVE

The objective of this study was to investigate and compare the hemodynamic and turbulence characteristics upon implantation of St Jude Medical (SJM) (St Jude Medical, St Paul, Minn) and On-X (On-X Life Technologies, Kennesaw, Ga) bileaflet mechanical valves. Both valves are considered highly successful bileaflet mechanical valves characterized by good clinical outcomes despite their numerous design differences. Although thromboembolism remains the main disadvantage of bileaflet mechanical valves, On-X valves have been shown to need less anticoagulation therapy.

METHODS

Hemodynamic assessment of a 23-mm On-X bileaflet mechanical valve and a 23-mm bileaflet SJM valve implanted in an aortic root was performed under pulsatile physiologic conditions. Time-resolved and phase-locked particle-image-velocimetry images and high-speed imaging data were acquired. Pressure gradients, effective orifice areas, dimensionless area index, leaflet position tracking, velocity, and principal Reynolds shear stress were calculated.

RESULTS

Pressure gradient for the On-X valve was 4.15 ± 0.099 mm Hg versus 4.75 ± 0.048 mm Hg for SJM (P < .001). Effective orifice area for the On-X valve was 2.61 ± 0.045 cm² versus 2.36 ± 0.022 cm² for SJM (P < .001). Area index was higher with SJM (0.87 ± 0.008) than with On-X (0.73 ± 0.013) (P < .001). On-X showed fluctuating leaflet behavior during systole, whereas SJM leaflets were stable. At peak systole, the maximal velocity with On-X was 1.86 m/s versus 2.33 m/s with SJM. Reynolds shear stress was higher with On-X compared with SJM at peak systole (95 vs 72 Pa). Higher velocity fluctuation was noted with the On-X valve.

CONCLUSIONS

This study shows that despite the design differences that characterize the On-X valve, the hemodynamic and turbulence parameters were not necessarily improved compared with SJM.

Application of Heparin/Collagen-REDV Selective Active Interface on ePTFE Films to Enhance Endothelialization and Anticoagulation

Expanded polytetrafluoroethylene (ePTFE) prosthetic valves have been widely used in clinical applications in Asian countries. However, these valves still have limits with regard to thrombosis, neointimal hyperplasia, restenosis, and valvar vegetation. The achievement of in situ endothelialization on implant materials is a promising way to overcome those limits. Here, heparin/collagen multilayers were fabricated on ePTFE films via a layer-by-layer (LBL) self-assembly technique, and then, the endothelial cell (EC) adhesive peptide sequence Arg-Glu-Asp-Val (REDV) was immobilized on the multilayers. After modification with the heparin/collagen multilayers with or without REDV peptide, less platelet activation and aggregation were observed, the blood coagulation time was increased, and the hemolysis rate was decreased compared to that on pristine ePTFE films. The REDV-functionalized ePTFE films positively impacted early EC adhesion, later cell proliferation and cell activity. The EC barrier was confirmed to be successfully achieved on the functionalized ePTFE film surface in vitro. The successful assembly of the REDV-functionalized heparin/collagen multilayer on ePTFE films improved the blood compatibility, anticoagulant properties, and cell compatibility of the films in vitro, and thus, represents a candidate approach for applications requiring quick in situ endothelialization in vivo.

Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide

A 75-year old woman with a history of coronary disease status post 3-vessel coronary artery bypass grafting (CABG) 8 years ago and a repeat one-vessel CABG 2 years ago in the setting of aortic valve replacement with a #19 mm St. Jude bileaflet mechanical valve for severe aortic stenosis presented with two to three weeks of progressive dyspnea and increasing substernal chest discomfort. Echocardiography revealed a gradient to 31 mmHg across her aortic valve, increased from a baseline of 13 mmHg five months previously. Fluoroscopy revealed thrombosis of her mechanical aortic valve. She was not a candidate for surgery given her multiple comorbidities, and fibrinolysis was contraindicated given a recent subdural hematoma 1 year prior to presentation. She was treated with heparin and eptifibatide and subsequently demonstrated resolution of her aortic valve thrombosis. We report the first described successful use of eptifibatide in addition to unfractionated heparin for the management of subacute valve thrombosis in a patient at high risk for repeat surgery or fibrinolysis.

Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician

Patients with prosthetic heart valves require chronic oral anticoagulation. In this clinical scenario, physicians must be mindful of the thromboembolic and bleeding risks related to chronic anticoagulant therapy. Currently, only vitamin K antagonists are approved for this indication. This paper reviews the main heart valve guidelines focusing on the use of oral anticoagulation in these patients.

Device Thrombogenicity Emulator (DTE)--design optimization methodology for cardiovascular devices: a study in two bileaflet MHV designs

Patients who receive prosthetic heart valve (PHV) implants require mandatory anticoagulation medication after implantation due to the thrombogenic potential of the valve. Optimization of PHV designs may facilitate reduction of flow-induced thrombogenicity and reduce or eliminate the need for post-implant anticoagulants. We present a methodology entitled Device Thrombogenicty Emulator (DTE) for optimizing the thrombo-resistance performance of PHV by combining numerical and experimental approaches. Two bileaflet mechanical heart valves (MHV) designs, St. Jude Medical (SJM) and ATS, were investigated by studying the effect of distinct flow phases on platelet activation. Transient turbulent and direct numerical simulations (DNS) were conducted, and stress loading histories experienced by the platelets were calculated along flow trajectories. The numerical simulations indicated distinct design dependent differences between the two valves. The stress loading waveforms extracted from the numerical simulations were programmed into a hemodynamic shearing device (HSD), emulating the flow conditions past the valves in distinct 'hot-spot' flow regions that are implicated in MHV thrombogenicity. The resultant platelet activity was measured with a modified prothrombinase assay, and was found to be significantly higher in the SJM valve, mostly during the regurgitation phase. The experimental results were in excellent agreement with the calculated platelet activation potential. This establishes the utility of the DTE methodology for serving as a test bed for evaluating design modifications for achieving better thrombogenic performance for such devices.

Numerical analysis on the hemodynamics and leaflet dynamics in a bileaflet mechanical heart valve using a fluid-structure interaction method

Bileaflet mechanical heart valves (BMHVs) are widely implanted to replace diseased heart valves but still suffer from complications such as hemolysis and platelet activation. These complications are closely related to both flow characteristics through the valves and leaflet dynamics. In this study, a fluid-structure interaction (FSI) simulation is performed to investigate the characteristics of physiological flow interacting with moving leaflets in a BMHV. The present FSI model uses both a finite volume computational fluid dynamics code and a finite element structure dynamics code to solve the governing equations for fluid flow and leaflet dynamics. In addition, a structural analysis is performed with the forces acting on the leaflet surfaces. From the analysis, detailed flow information and leaflet behavior are quantified for a cardiac cycle. The results show that the present FSI model performs well at predicting the overall flow patterns interacting with the moving leaflets and leaflet behavior in the BMHV.

Mitral valve-sparing procedures and prosthetic heart valve failure: a case report

Prosthetic heart valve dysfunction due to thrombus or pannus formation can be a life-threatening complication. The present report describes a 47-year-old woman who developed valvular cardiomyopathy after chorda-sparing mitral valve replacement, and subsequently underwent heart transplantation for progressive heart failure. The explanted mitral valve prosthesis showed significant thrombus and pannus leading to reduced leaflet mobility and valvular stenosis. The present report illustrates the role of the subvalvular apparatus and pannus in prosthesis dysfunction.

Engineering the heart piece by piece: state of the art in cardiac tissue engineering

According to the National Transplant Society, more than 7000 Americans in need of organs die every year owing to a lack of lifesaving organs. Bioengineering 3D organs in vitro for subsequent implantation may provide a solution to this problem. The field of tissue engineering in its most rudimentary form is focused on the developed of transplantable organ substitutes in the laboratory. The objective of this article is to introduce important technological hurdles in the field of cardiac tissue engineering. This review starts with an overview of tissue engineering, followed by an introduction to the field of cardiovascular tissue engineering and finally summarizes some of the key advances in cardiac tissue engineering; specific topics discussed in this article include cell sourcing and biomaterials, in vitro models of cardiac muscle and bioreactors. The article concludes with thoughts on the utility of tissue-engineering models in basic research as well as critical technological hurdles that need to be addressed in the future.

Pathology of infectious and inflammatory diseases in prosthetic heart valves

Prosthetic heart valves, both mechanical and biological (xenograft valves, stented or unstented), show an inflammatory reaction (infective endocarditis), associated predominantly with bacterial/fungal infection. Somewhat surprisingly, no immune-mediated reaction has been reported thus far. This may, among other reasons, be related to the fact that the tissues are "fixed" with aldehydes and are virtually isolated from host circulation, separated by synthetic material (the valve stent and the fabric covering it). Stentless valves (especially these without fabric covering them), however, have no such "isolation" from the host circulation. While the Toronto-Stentless Porcine Valve has a covering of fabric, the Medtronic Freestyle valve has no such covering. It is perhaps not so surprising therefore that at the intermediate time point of 5 to 6 years, some valves are beginning to show such an immune reaction.

Tissue engineering a functional aortic heart valve: an appraisal

Valvular heart disease is an important cause of morbidity and mortality, and currently available substitutes for failing hearts have serious limitations. A new promising alternative that may overcome these shortcomings is provided by the relatively new field of tissue engineering (TE). TE techniques involve the growth of autologous cells on a 3D matrix that can be a biodegradable polymer scaffold, or an acellular tissue matrix. These approaches provide the potential to create living matrix valve structures with an ability to grow, repair and remodel within the recipient. This article provides an appraisal of artificial heart valves and an overview of developments in TE that includes the current limitations and challenges for creating a fully functional valve. Biomaterials and stem cell technologies are now providing the potential for new avenues of research and if combined with advances in the rapid prototyping of biomaterials, the engineering of personalized, fully functional, and autologous tissue valve replacements, may become a clinical alternative.